BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

752 related articles for article (PubMed ID: 32099092)

  • 1. Organoid models of gastrointestinal cancers in basic and translational research.
    Lau HCH; Kranenburg O; Xiao H; Yu J
    Nat Rev Gastroenterol Hepatol; 2020 Apr; 17(4):203-222. PubMed ID: 32099092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal cancer organoids-applications in basic and translational cancer research.
    Seidlitz T; Stange DE
    Exp Mol Med; 2021 Oct; 53(10):1459-1470. PubMed ID: 34663939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promising preclinical patient-derived organoid (PDO) and xenograft (PDX) models in upper gastrointestinal cancers: progress and challenges.
    Gao J; Lan J; Liao H; Yang F; Qiu P; Jin F; Wang S; Shen L; Chao T; Zhang C; Zhu Y
    BMC Cancer; 2023 Dec; 23(1):1205. PubMed ID: 38062430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling colorectal cancers using multidimensional organoids.
    Sayed IM; El-Hafeez AAA; Maity PP; Das S; Ghosh P
    Adv Cancer Res; 2021; 151():345-383. PubMed ID: 34148617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer research using organoid technology.
    Kretzschmar K
    J Mol Med (Berl); 2021 Apr; 99(4):501-515. PubMed ID: 33057820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity.
    Calandrini C; Schutgens F; Oka R; Margaritis T; Candelli T; Mathijsen L; Ammerlaan C; van Ineveld RL; Derakhshan S; de Haan S; Dolman E; Lijnzaad P; Custers L; Begthel H; Kerstens HHD; Visser LL; Rookmaaker M; Verhaar M; Tytgat GAM; Kemmeren P; de Krijger RR; Al-Saadi R; Pritchard-Jones K; Kool M; Rios AC; van den Heuvel-Eibrink MM; Molenaar JJ; van Boxtel R; Holstege FCP; Clevers H; Drost J
    Nat Commun; 2020 Mar; 11(1):1310. PubMed ID: 32161258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of organoids in translational research of human diseases with a particular focus on gastrointestinal cancers.
    Nguyen R; Bae SDW; Zhou G; Read SA; Ahlenstiel G; George J; Qiao L
    Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188350. PubMed ID: 32007597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-derived organoid models help define personalized management of gastrointestinal cancer.
    Aberle MR; Burkhart RA; Tiriac H; Olde Damink SWM; Dejong CHC; Tuveson DA; van Dam RM
    Br J Surg; 2018 Jan; 105(2):e48-e60. PubMed ID: 29341164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Single-Cell Technique to Increase Yield and Use of Gastrointestinal Cancer Organoids for Personalized Medicine Application.
    Gao M; Harper MM; Lin M; Qasem SA; Patel RA; Mardini SH; Gabr MM; Cavnar MJ; Pandalai PK; Kim J
    J Am Coll Surg; 2021 Apr; 232(4):504-514. PubMed ID: 33253861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress and perspective of organoid technology in cancer-related translational medicine.
    Lin Y; Jiang L; He Q; Yuan M; Cao J
    Biomed Pharmacother; 2022 May; 149():112869. PubMed ID: 35358798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant ascites-derived organoid (MADO) cultures for gastric cancer in vitro modelling and drug screening.
    Li J; Xu H; Zhang L; Song L; Feng D; Peng X; Wu M; Zou Y; Wang B; Zhan L; Hua G; Zhan X
    J Cancer Res Clin Oncol; 2019 Nov; 145(11):2637-2647. PubMed ID: 31598791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-derived organoids for personalized gallbladder cancer modelling and drug screening.
    Yuan B; Zhao X; Wang X; Liu E; Liu C; Zong Y; Jiang Y; Hou M; Chen Y; Chen L; Zhang Y; Wang H; Fu J
    Clin Transl Med; 2022 Jan; 12(1):e678. PubMed ID: 35075805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organoid Models of Colorectal Pathology: Do They Hold the Key to Personalized Medicine? A Systematic Review.
    DeHaan RK; Sarvestani SK; Huang EH
    Dis Colon Rectum; 2020 Nov; 63(11):1559-1569. PubMed ID: 32868555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic heterogeneity of 2D organoid reflects clinical tumor characteristics.
    Fujino S; Ito A; Ohue M; Yasui M; Mizushima T; Doki Y; Mori M; Miyoshi N
    Biochem Biophys Res Commun; 2019 May; 513(2):332-339. PubMed ID: 30955861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unlocking the potential of organoids in cancer treatment and translational research: An application of cytologic techniques.
    Abd El-Salam MA; Troulis MJ; Pan CX; Rao RA
    Cancer Cytopathol; 2024 Feb; 132(2):96-102. PubMed ID: 37843532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organoid Cultures Derived From Patients With Papillary Thyroid Cancer.
    Chen D; Tan Y; Li Z; Li W; Yu L; Chen W; Liu Y; Liu L; Guo L; Huang W; Zhao Y
    J Clin Endocrinol Metab; 2021 Apr; 106(5):1410-1426. PubMed ID: 33524147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.
    Praharaj PP; Bhutia SK; Nagrath S; Bitting RL; Deep G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):117-127. PubMed ID: 29360544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Organoid technology for personalized pancreatic cancer therapy.
    Bengtsson A; Andersson R; Rahm J; Ganganna K; Andersson B; Ansari D
    Cell Oncol (Dordr); 2021 Apr; 44(2):251-260. PubMed ID: 33492660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use and application of 3D-organoid technology.
    Artegiani B; Clevers H
    Hum Mol Genet; 2018 Aug; 27(R2):R99-R107. PubMed ID: 29796608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-Generation Modeling of Cancer Using Organoids.
    Love JR; Karthaus WR
    Cold Spring Harb Perspect Med; 2024 Jun; 14(6):. PubMed ID: 37734867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.